Pirfenidone in Adult Hospitalized Patients With COVID-19

This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

Inclusion Criteria:Subjects Age ≥ 18 Willing and able to provide written informed consentSARS-CoV-2 infection confirmed by PCR test/antigen dectection or positive serologiesTime of illness onset ≥8 daysHave findings consistent with interstitial lung disease found on CT scanWilling not use other investigational agents of anti-fibrosisExclusion Criteria:Pre-existing severe liver diseasePre-existing severe chronic kidney diseasePre-existing interstitial lung diseasePre-existing severe COPD or other structural lung diseaseReceiving invasive mechanical ventilationCurrently Pregnant or Breast FeedingPoor baseline health conditoinDisability to complete lung function testReceiving pirfenidone wthin half-year